J.P. Morgan Day 4: Setting Goals For The Year Ahead
Updates from Viatris, Chi-Med, Novo Nordisk, Sangamo, Intercept, ImmunoGen
Executive Summary
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Viatris debuts; Chi-Med charts its own path; Novo takes another go at obesity; Sangamo moves forward with CAR-Treg; Intercept readies for resubmission; and ImmunoGen is relying on a safety advantage for its ADC.
You may also be interested in...
Chi-Med's Surufatinib, Generic Ibrance Among Latest China Approvals
China's innovative drug makers step into the spotlight by grabbing green lights for cancer drugs in the country's latest batch of product approvals.
Novo Nordisk Takes The Plunge Into Alzheimer's With Phase III Semaglutide Trial
Analysis of cardiovascular studies show GLP-1 drugs are associated with a 53% reduced risk of developing Alzheimer’s disease.
Up To 9,000 Jobs At Risk As Viatris Kicks Off $1bn Restructuring Scheme
With a goal of reducing its cost base by at least $1bn by 2024, Viatris has delivered plans to significantly restructure its global manufacturing network. Up to 20% of Viatris’ 45,000-strong workforce could be impacted by the initiative which will see the firm close, divest or downsize 15 of its manufacturing plants around the globe.